Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer.

Allensworth JL, Evans MK, Bertucci F, Aldrich AJ, Festa RA, Finetti P, Ueno NT, Safi R, McDonnell DP, Thiele DJ, Van Laere S, Devi GR.

Mol Oncol. 2015 Jun;9(6):1155-68. doi: 10.1016/j.molonc.2015.02.007. Epub 2015 Feb 21.

2.

Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization.

Williams KP, Allensworth JL, Ingram SM, Smith GR, Aldrich AJ, Sexton JZ, Devi GR.

Cancer Lett. 2013 Aug 28;337(1):77-89. doi: 10.1016/j.canlet.2013.05.017. Epub 2013 May 17.

3.

Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.

Allensworth JL, Sauer SJ, Lyerly HK, Morse MA, Devi GR.

Breast Cancer Res Treat. 2013 Jan;137(2):359-71. doi: 10.1007/s10549-012-2352-6. Epub 2012 Dec 7.

PMID:
23225169
4.

Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines.

Rangwala F, Williams KP, Smith GR, Thomas Z, Allensworth JL, Lyerly HK, Diehl AM, Morse MA, Devi GR.

BMC Cancer. 2012 Sep 10;12:402. doi: 10.1186/1471-2407-12-402.

5.

XIAP inhibition and generation of reactive oxygen species enhances TRAIL sensitivity in inflammatory breast cancer cells.

Allensworth JL, Aird KM, Aldrich AJ, Batinic-Haberle I, Devi GR.

Mol Cancer Ther. 2012 Jul;11(7):1518-27. doi: 10.1158/1535-7163.MCT-11-0787. Epub 2012 Apr 16.

6.

Cytotoxic effects of Mn(III) N-alkylpyridylporphyrins in the presence of cellular reductant, ascorbate.

Ye X, Fels D, Tovmasyan A, Aird KM, Dedeugd C, Allensworth JL, Kos I, Park W, Spasojevic I, Devi GR, Dewhirst MW, Leong KW, Batinic-Haberle I.

Free Radic Res. 2011 Nov;45(11-12):1289-306. doi: 10.3109/10715762.2011.616199. Epub 2011 Sep 27.

7.

ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells.

Aird KM, Allensworth JL, Batinic-Haberle I, Lyerly HK, Dewhirst MW, Devi GR.

Breast Cancer Res Treat. 2012 Feb;132(1):109-19. doi: 10.1007/s10549-011-1568-1. Epub 2011 May 11.

8.

The effect of epsilon aminocaproic acid on preservation of stored coagulation factors.

Hunter DT, Allensworth JL.

Agressologie. 1968 Jul-Aug;9(4):521-4. No abstract available.

PMID:
5722618
9.

Improved coagulation screening by an activated recalcification test.

Hunter DT, Allensworth JL.

J Clin Pathol. 1967 May;20(3):244-8.

10.

Quantitative assay of the Hageman factor.

Hunter DT Jr, Allensworth JL.

Am J Clin Pathol. 1967 Apr;47(4):448-53. No abstract available.

PMID:
6021547
11.

Plasmin assay. A new method for the estimation of physiologically active plasmin.

Hunter DT Jr, Allensworth JL.

Hemostase. 1966 May-Jun;6(2):201-6. No abstract available.

PMID:
4224766
12.

A MODIFIED FIBRINOGEN ASSAY.

HUNTER DT, ALLENSWORTH JL.

Tech Bull Regist Med Technol. 1965 Aug;35:145-9. No abstract available.

PMID:
14347453

Supplemental Content

Loading ...
Support Center